ZERO Prostate Cancer’s Post

Delve into another one of our articles, ��Radioisotopes and Their Future in Medicine”. Gain insight into how these tools reshape cancer treatment, from fundamentals, to advanced techniques like targeted alpha particle therapy. Uncover the personalized approach revolutionizing oncology. Stay informed on cutting-edge medical innovation by reading down below! #MedicalAdvancements #PrecisionMedicine ⬇️⬇️⬇️⬇️⬇️ https://lnkd.in/gf_n6F_n

Recently, we were asked what makes Genomate unique within the larger field of precision medicine. There's no one better to answer this question than Istvan Petak, MD, PhD, the visionary behind the solution ↘ The full conversation with the lovely DrugBank team is available here: https://lnkd.in/gys2zr_y 🎯 Genomate is the world’s first proven AI-powered clinical decision support system for precision oncology, transforming the lives of countless cancer patients.

Thanks to Chandler Park, M.D., F.A.C.P. OncLive for allowing me to comment on the important data presented at #ESMO23! Excited to see a multiplicity of ADCs showing improved outcomes for patients with metastatic breast cancer, the latest being the Trop2-targeted Dato-DXd. We’re rapidly improving our understanding on how ADCs work, and will hopefully soon understand better how to sequence them in the clinic, and how to prevent certain side effects related to the use of ADCs.

CELLSEARCH® CTC count proves its clinical utility in guiding therapeutic strategy supporting patient care in HR+/HER2- metastatic breast cancer

Really excited to present a Keynote talk at the OncoVision Virtual Conference next week! Come join me and learn more about CGP and NGS in oncology diagnostics and precision medicine…details below… #oncology #precisionmedicine #cgp #oncovision #illumina

Findings from a recent precision oncology report warrant renewed attention to the completion of molecular genotyping before 1L therapy. Among patients with mNSq NSCLC in a real-world cohort, availability of molecular genotyping results before 1L therapy was associated with significantly better OS. Concurrent tissue and plasma testing was associated with a higher odds of availability of results before 1L therapy. Read the full study: #NSCLC #LungCancer

#DYK Dr. Tian Zhang, of the University of Texas Southwestern Medical Center, leads Alliance A031704 (PDIGREE study) that looks to see how well nivolumab and ipilimumab, followed by nivolumab versusu cabozantinib and nivolumab, work in treating patients with untreated advanced renal cell cancer. To learn more about the PDIGREE study, visit https://lnkd.in/g_vYCUpJ #NCI #NCTN

For Clinical Research Associates and oncology professionals: Explore the future of oncology trials with our latest white paper, 'PRECISION ONCOLOGY: Global Clinical Trial Landscape (2024)' https://ow.ly/7fLp50SoAb5, diving deep into the evolving strategies and trends shaping precision medicine in cancer research.

Findings from a recent precision oncology report warrant renewed attention to the completion of molecular genotyping before 1L therapy. Among patients with mNSq NSCLC in a real-world cohort, availability of molecular genotyping results before 1L therapy was associated with significantly better OS. Concurrent tissue and plasma testing was associated with a higher odds of availability of results before 1L therapy. Read the full study: #NSCLC #LungCancer

Findings from a recent precision oncology report warrant renewed attention to the completion of molecular genotyping before 1L therapy. Among patients with mNSq NSCLC in a real-world cohort, availability of molecular genotyping results before 1L therapy was associated with significantly better OS. Concurrent tissue and plasma testing was associated with a higher odds of availability of results before 1L therapy. Read the full study: #NSCLC #LungCancer